^
    2d
    A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA) (clinicaltrials.gov)
    P4, N=15, Active, not recruiting, University of Alabama at Birmingham | Recruiting --> Active, not recruiting
    Enrollment closed
    2d
    NCI-2020-01626: Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=79, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | N=60 --> 79 | Trial completion date: Dec 2029 --> Apr 2030
    Enrollment closed • Enrollment change • Trial completion date
    |
    Jakafi (ruxolitinib) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • busulfan
    3d
    A clinical study of ruxolitinib combined with reduced-dose HLH-1994 regimen in the treatment of adult hemophagocytic lymphohistiocytosis (ChiCTR2500115370)
    P=N/A, N=20, Not yet recruiting, Shandong Provincial Qianfoshan Hospital; Shandong Provincial Qianfoshan Hospital
    New trial
    |
    Jakafi (ruxolitinib)
    3d
    A real-world study on the influencing factors of the efficacy of ruxolitinib cream in the treatment of vitiligo (ChiCTR2500115141)
    P=N/A, N=170, Not yet recruiting, Peking University Third Hospital; Peking University Third Hospital
    New trial
    3d
    Clinical study on the safety and efficacy of gecacitinib hydrochloride tablets in the treatment of mild to moderate acute graft-versus-host disease (ChiCTR2500113066)
    P=N/A, N=15, Not yet recruiting, Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital
    New trial
    3d
    A Clinical Study on the Efficacy and Safety of JAK/ACVR1 Inhibitors in the Treatment of Steroid-resistant Chronic Graft-versus-Host Disease (ChiCTR2500112276)
    P=N/A, N=40, Not yet recruiting, The Second Affiliated Hospital of the Army Medical University; The Second Affiliated Hospital of the Army Medical University
    New trial
    3d
    Real-world study of The efficacy and safety of The JAK inhibitor Baricitinib and Ritlecitinib for the treatment of severe alopecia areata (ChiCTR2500114501)
    P=N/A, N=150, Completed, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New trial
    |
    Litfulo (ritlecitinib)
    3d
    A Clinical Study on the Safety and Efficacy of Gecacitinib Hydrochloride Tablets in the Treatment of Myelodysplastic Syndromes (MDS) and Myelodysplastic Syndromes/Myeloproliferative Neoplasm （MDS/MPN）Patients with Anemia. (ChiCTR2500113178)
    P4, N=48, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.; Institute of Hematolog
    New P4 trial
    3d
    A randomized, double-blind, excipi-controlled, multicenter Phase III clinical study to evaluate the efficacy and safety of ruxolitinib gel (HDM3010) in adult subjects with mild to moderate pruritus nodules (ChiCTR2600117276)
    P3, N=360, Not yet recruiting, Hangzhou First People's Hospital; Hangzhou First People's Hospital
    New P3 trial
    |
    Jakafi (ruxolitinib)
    3d
    A Phase 2 Study of Gecacitinib in Patients with Chronic Neutrophilic Leukemia (CNL) and myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis (MDS/MPN-SFCB1-T) (ChiCTR2500113793)
    P2, N=28, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.; Institute of Hematolog
    New P2 trial
    |
    SF3B1 (Splicing Factor 3b Subunit 1)
    3d
    Efficacy and Safety of Ruxolitinib Combined with Decitabine in Treating High-Risk Myelofibrosis Patients: A Prospective, Multicenter, Phase II Clinical Study Protocol (ChiCTR2600117487)
    P2, N=36, Not yet recruiting, The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine
    New P2 trial
    |
    Jakafi (ruxolitinib) • decitabine
    3d
    Phase IIa study on the safety and efficacy of Flonoltinib Maleate Tablets in the treatment of patients with polycythemia vera (ChiCTR2500111413)
    P2, N=60, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS);West China Hospital of Sichuan University;Shengjin
    New P2 trial
    |
    hydroxyurea • flonoltinib